Market Research Report
Global Biosimilar Monoclonal Antibodies Forecast 2018-2028: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab
|Published by||Visiongain Ltd||Product code||275993|
|Published||Content info||204 Pages
Delivery time: 1-2 business days
|Global Biosimilar Monoclonal Antibodies Forecast 2018-2028: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab|
|Published: February 27, 2018||Content info: 204 Pages||
The global biosimilar monoclonal antibodies market is expected to reach $5.9bn in 2023 and is estimated to grow at a CAGR of 19% from 2016 to 2028.
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 204-page report you will receive 72 tables and 74 figures- all unavailable elsewhere.
The 204-page report provides clear detailed insight into the global biosimilar monoclonal antibodies market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
This report profiles 10 leading companies either with biosimilar mAbs already on the market or in the pipeline
Our study discusses strengths, weaknesses, opportunities and threats affecting the biosimilar monoclonal antibodies market
Visiongain's study is intended for anyone requiring commercial analyses for the biosimilars monoclonal antibodies market. You find data, trends and predictions.